e-learning
resources
Vienna 2009
Sunday, 13.09.2009
Airways remodelling
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Osteopontin in severe refractory asthma
V. Delimpoura, P. Bakakos, D. Simoes, E. Tseliou, V. Bessa, G. Hillas, G. Papadaki, K. Matzouranis, C. Roussos, S. Papiris, S. Loukides (Athens, Greece)
Source:
Annual Congress 2009 - Airways remodelling
Session:
Airways remodelling
Session type:
Oral Presentation
Number:
1331
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
V. Delimpoura, P. Bakakos, D. Simoes, E. Tseliou, V. Bessa, G. Hillas, G. Papadaki, K. Matzouranis, C. Roussos, S. Papiris, S. Loukides (Athens, Greece). Osteopontin in severe refractory asthma. Eur Respir J 2009; 34: Suppl. 53, 1331
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Management of Severe Asthma in Pediatric Patients by an Interdisciplinary Team in a Public Hospital Setting.
Related content which might interest you:
Eosinophilic refractory inflammation in OCS-dependent severe asthma
Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments
Year: 2021
Severe therapy-resistant asthma
Source: International Congress 2016 – PG8 Paediatric asthma
Year: 2016
Late-onset persistent eosinophilic severe asthma
Source: International Congress 2015 – Severe asthma phenotyping
Year: 2015
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma
Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues
Year: 2017
Distribution of biomarkers in severe asthma and severe uncontrolled asthma
Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research
Year: 2021
Effect of anti-IL5 treatment on symptoms of chronic rhinosinusitis, otitis and hearing loss in patients with severe eosinophilic asthma
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Effect of ABPA treatment in severe asthma patients with acute and relapsed disease
Source: Virtual Congress 2020 – Advances in asthma treatment
Year: 2020
Markers of T2-inflammation in patients with severe asthma and concomitant COPD
Source: Virtual Congress 2020 – News on clinical evaluation of bronchiectasis, cough and inflammatory disease
Year: 2020
Management of difficult-to-treat severe asthma
Source: Eur Respir Mon 2011; 51: 282-296
Year: 2011
Predictors of severe exacerbations in patients with moderate and severe asthma
Source: International Congress 2018 – Determinants and monitoring of asthma control
Year: 2018
Management of severe and difficult-to-treat asthma
Source: Annual Congress 2013 –Severe asthma: moving from phenotyping to endotyping
Year: 2013
IL-33 in patients with severe uncontrolled allergic asthma
Source: International Congress 2017 – "Alarming" immunological patterns in asthma
Year: 2017
Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy
Source: Virtual Congress 2020 – Monoclonal antibodies in asthma
Year: 2020
Experience with Mepolizumab in a cohort of patients with eosinophilic severe persistent asthma
Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma
Year: 2019
Characterisation of patients with difficult-to-treat and treatment-resistant severe asthma
Source: Annual Congress 2012 - Airway diseases: from invasive to noninvasive biomarkers
Year: 2012
Immunotherapy in severe asthma
Source: ERS webinar 2021: Immunotherapy in severe asthma
Year: 2021
Clinical features of steroid-resistant patients with severe steroid-dependent bronchial asthma
Source: Eur Respir J 2004; 24: Suppl. 48, 133s
Year: 2004
Impact of moderate and severe exacerbations in severe COPD patients
Source: International Congress 2018 – How far are we in terms of predicting mortality and exacerbations in COPD?
Year: 2018
Severe asthma
Source: International Congress 2014 – ERS/CTS China Day: advances in asthma and COPD
Year: 2014
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept